Telix Pharmaceuticals Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Telix Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Telix Pharmaceuticals is a biopharmaceutical enterprise focused on radiopharmaceuticals and molecularly targeted radiation technologies. The group conducts activities across three main operating segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its portfolio includes commercial diagnostics such as Illuccix (TLX591-CDx), alongside specialized diagnostic imaging candidates such as Zircaix, SENSEI, and Dedicaid QDOSE. The Therapeutics division focuses on clinical radiotherapeutic treatments, including TLX101-Tx, TLX591-Tx, TLX66-Tx, and TLX300-Tx. In addition, the Manufacturing Solutions segment delivers radiopharmacy operations, production capabilities, and technical supply chain services to healthcare providers, research collaborators, and commercial partners.
The enterprise maintains an international operating presence and property assets across several countries, including Australia, the United States, Belgium, Canada, and the United Kingdom. Its manufacturing and production facilities include operations located in Brussels South and Sacramento. Operating under an Australian corporate structure, the entity conducts its principal activities and corporate oversight from Australia, supported by operating subsidiaries and production hubs spanning North America and Europe.
Summary of the business section of Telix Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Telix Pharmaceuticals Ltd
- Headquarters
- North Melbourne, C3
- Address
- 55 Flemington Road 3051
- Phone
- 61 3 9093 3855
- Employees
- 1,120, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- C3
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers, Melbourne, Australia
Stock & identifiers
- Ticker
- TLX
- Other tickers
- TLPPF
- Exchange
- Nasdaq
- Shares outstanding
- 339M, Dec 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 2007191
- CUSIP
- 87961M105
- ISIN
- US87961M1053
- LEI
- 894500HTWOOGIHLLSB86
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christian Behrenbruch | MD & Group CEO, Director | 20,996,941 |
| Darren Charlton Smith | Group Chief Financial Officer | 13,992 |
| David Norman Cade | Group Chief Medical Officer | 373,133 |
| Darren Joel Patti | Group Chief Operating Officer | 25,558 |
| David N. Gill | Director | – |
| William R. Jellison | Director | – |
| Maria Rivas | Director | – |
| Mark Alexander Nelson | Director | 3,628,750 |
| Jann Elizabeth Skinner | Director | 595,000 |
| Marie Elizabeth McDonald | Director | 3,719 |
Employees
Headcount reported in annual reports
“As of December 31, 2025 , we had 1,120 full-time employees and 64 part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 10, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |